A Study Evaluating Potential Disease-Mediated Drug-Drug Interaction in Adult Participants With Active Eosinophilic Esophagitis Receiving Cendakimab
Public ClinicalTrials.gov record NCT05175352. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Open-label, Single-sequence Study to Evaluate Potential Disease-mediated Drug-drug Interaction With Selected Cytochrome P450 Substrates in Adult Subjects With Active Eosinophilic Esophagitis Receiving Cendakimab
Study identification
- NCT ID
- NCT05175352
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Celgene
- Industry
- Enrollment
- 16 participants
Conditions and interventions
Conditions
Interventions
- CYP substrates Drug
- Cendakimab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 6, 2022
- Primary completion
- Oct 10, 2024
- Completion
- Oct 10, 2024
- Last update posted
- Dec 19, 2024
2022 – 2024
United States locations
- U.S. sites
- 12
- U.S. states
- 9
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 004 | Tucson | Arizona | 85715 | — |
| Local Institution - 001 | Los Angeles | California | 90067 | — |
| Local Institution - 022 | San Diego | California | 92103-5639 | — |
| Local Institution - 016 | Bristol | Connecticut | 06010-5142 | — |
| Local Institution - 002 | Inverness | Florida | 34452 | — |
| Local Institution - 010 | Miami | Florida | 33144-2035 | — |
| Local Institution - 021 | Plantation | Florida | 33324-3345 | — |
| Local Institution - 020 | Gurnee | Illinois | 60031-5711 | — |
| Local Institution - 008 | Iowa City | Iowa | 52242 | — |
| Local Institution - 003 | Albuquerque | New Mexico | 87106-4725 | — |
| Local Institution - 018 | Durham | North Carolina | 27710 | — |
| Local Institution - 012 | Columbus | Ohio | 43235 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05175352, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 19, 2024 · Synced Apr 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05175352 live on ClinicalTrials.gov.